Gravitas Education ADR Cl. A Aktie

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of drug therapies and diagnostics to improve the monitoring and treatment of depression, today announced that the Board has approved the issuance of 4,000,001 common shares at $0.71/share in relation to the settlement of the $3.5 Million (CDN) of debenture announced on January 10, 2025. "We are pleased to announce that instructions to issue 4,000,001 shares for a total value of $2,840,000.71 in settlement of the debenture has been completed.» Mehr auf newsfilecorp.com

Vancouver, British Columbia--(Newsfile Corp. - January 10, 2025) - MYND Life Sciences (CSE: MYND) (OTC Pink: MYNDF) ("MYND" or the "Company") a clinical-stage life sciences company committed to the development and commercialization of a biomarker tool for monitoring depression, today announced that the application to end its debenture has been successfully accepted by both the debenture holders and the regulatory commission. This announcement confirms the removal of $3.5 Million (CDN) of debt from its balance sheet.» Mehr auf newsfilecorp.com

SEATTLE , Jan. 6, 2025 /PRNewswire/ -- Mynd.ai, Inc. ("Mynd" or the "Company") (NYSE American: MYND) today announced that its subsidiary, Promethean, has released its most anticipated, unified interactive flat panel display (IFPD) and software solution—the all-new ActivPanel 10 and Promethean ActivSuite. "Specifically designed to support freedom of choice, simplicity, and adaptability, the ActivPanel 10 and Promethean ActivSuite solution allows educators and business leaders to choose their preferred operating system and meet users exactly where they are when they need it, with no added hassle, stress, or complicated training," said Vin Riera, Mynd's Chief Executive Officer.» Mehr auf prnewswire.com